Advantage Novo As Victoza Gets CV Benefit Okay in Europe
Victoza is the only drug in the GLP-1 class in Europe to have a label that includes the prevention of CV events (and only the second antidiabetic after Boehringer Ingelheim/Lilly’s SGLT2 inhibitor Jardiance) which will help slow down market share loss to Lilly's Trulicity.
You may also be interested in...
Novo Nordisk Says More To Victoza Outcomes Benefit Than A GLP-1 Class Effect
Novo Nordisk's ESC satellite symposium on heels of FDA approval of CV event prevention claim for Victoza highlights differences compared to Sanofi's competing Lyxumia, which failed an outcomes study.
Novo Nordisk: Semaglutide Heralds Commercial Dawn Of Obesity Market
The Danish group expects its experimental GLP-1 semaglutide to prove so effective and safe in fighting obesity that it will spur commercial viability for medical treatment of the condition.
Semaglutide Should Transform Novo Nordisk's Prospects, CSO Says
Novo Nordisk's investigational GLP-1 agonist semaglutide promises to elevate the Danish group's product offering and market position, its CSO says in an interview with Scrip.